ENDRA Life Sciences' mission is to bring new capabilities to ultrasound and broaden access to better healthcare.
ENDRA's Photo-Acoustic Nexus-128 system is currently used by leading global medical researchers to screen and modify disease models.
ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS™) system to enable clinicians to visualize human tissue composition, function and temperature in ways previously possible only with CT & MRI -- at a fraction of the cost, and at the point-of-care.
ENDRA's first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease, which affects over 1 billion people globally.
|Oct 16, 2018||ENDRA Life Sciences Receives Approval to Initiate Human Studies of its TAEUS(TM) Device Targeting Non-Alcoholic Fatty Liver Disease|
|Oct 15, 2018||ENDRA Life Sciences Announces Closing of Public Offering and Exercise of Over-Allotment Option|
|Oct 11, 2018||ENDRA Life Sciences Inc. Prices Public Offering of Common Stock|
|Oct 10, 2018||ENDRA Life Sciences Inc. Announces Proposed Public Offering of Common Stock|
|Aug 29, 2018||ENDRA Life Sciences to Showcase TAEUS(TM) Liver Application at the EASL Non-Alcoholic Fatty Liver Disease Summit in Geneva Switzerland on September 20-22, 2018|
|Day Range||3.88 - 5.62|
|52 Week Range||1.55 - 5.88|
|Bid/Ask||4.41 / 4.55|
|Bid/Ask Size||100 X 500|
|Market Cap||17.69 million|
|Shares Outstanding||3.92 million|
|Dividend/Yield||0.00 / 0.00%|
|P/E Ratio (TTM)||N/A|